Vittoria Biotherapeutics
A clinical-stage cell therapy company developing novel CAR-T cell therapies.
Based on technology exclusively licensed from the University of Pennsylvania, the company’s proprietary Senza5 platformutilises the antitumor potential of engineered T cells, with pipeline applications in oncology and autoimmune diseases.
Vittoria hopes to advance its lead program, VIPER-101, into the clinic for the treatment of T-cell lymphoma.
Latest Vittoria Biotherapeutics News & Features
16 April 2024
27 February 2024
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze